Xbrane Biopharma AB (Nasdaq Stockholm: XBRANE)

https://www.xbrane.com

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product candidate XlucaneTM is a biosimilar on the original drug Lucentis®, a VEGFa inhibitor used in the treatment of a number of severe eye diseases. A global pivotal phase III study is ongoing for XlucaneTM and launch of the product is expected second half of 2022. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. *

	Start	2015-12-31 renamed (approx)
	Group	Xbrane (Group)
	Predecessor	Xbrane Bioscience AB
	Industry	DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics)
	Industry 2	biopharmaceutical production technology
	Person	Åmark, Martin (Xbrane 2020 CEO9
	Person 2	Lindquist, Anette (Xbrane 2020 CFO + IR)

	Region	Stockholm
	Country	Sweden
	City	n. a.
		Address record changed: 2021-12-06

Basic data	Employees	B: 11 to 50 (2020-12-31)
	Currency	SEK
	Profit	-226,026,000 (2020-12-31)
	Cash	243,139,000 (2020-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)